Hefang Venture Capital Invests in Drimmunity/Tcelltech to Advance Solid Tumor Immunotherapy

Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd. was establishedIn April 2017, it is a clinical-stage innovative pharmaceutical company focused on the development of immunotherapy drugs for solid tumors.Founded by pioneers in tumor immunology, Professor Chenli Ping, and expert in immunocyte therapy, Professor Huang Gangxiong. Core pipelineTX-103 is the world's first B7-H3 CAR-T cell therapy product to enter registrational clinical trials and conduct international clinical trials, targeting solid tumors such as recurrent glioblastoma (rGBM).Glioblastoma (GBM) is the most common primary intracranial malignant tumor, with 45,000 and 11,000 newly diagnosed patients annually in China and the United States, respectively. Almost all patients relapse after first-line standard treatment. The median overall survival (mOS) for recurrent patients is only 6-8 months, and the recurrence is associated with increased aggressiveness. Effective subsequent treatment options are lacking, representing a significant unmet clinical need.

TX-103 has demonstrated excellent efficacy and safety in early clinical trials,Can significantly extend mOS and improve one-year survival rate in rGBM patients`, and it is well-tolerated, with the potential to break through the bottleneck of existing therapies. Currently, a global Phase I clinical trial is underway.`

Moreover, based on the founding team's profound expertise and global leadership in tumor immunology, Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd. is concurrently developing the next generation of universal-type/In vivo cell therapy and T-cell engager platform, striving to build a world-leading solid tumor immunotherapy platform company.

For more details, please click [Read Original] below.

The content of this article is reproduced fromFuzhou Tuoxin Tiancheng Biotechnology Co., Ltd.Official Account

About TusPark Ventures

TusPark VenturesReorganized and established in 2014 under the strategic backdrop of promoting the transformation of scientific and technological achievements at Tsinghua University, TusPark Ventures is a professional investment management institution primarily focused on early-stage investments in science and technology innovation enterprises. TusPark Ventures concentrates on key areas such as life sciences, medical devices, information technology, and modern manufacturing, with a long-term focus on investing in innovative enterprises with core hard technologies. It also features incubation investments in scientific and technological achievements by university and top-tier hospital clinical experts. Currently, TusPark Ventures manages nearly 4 billion yuan in funds, with nearly 100 accumulated investment projects, supporting scientists and entrepreneurs with significant research discoveries and technological innovations to achieve "commercial transformation from 0 to 1." At the same time, it consistently adheres to selecting high-barrier "first-of-its-kind technologies" for early-stage investment. With outstanding performance, TusPark Ventures has received honors such as being ranked in the “Top 50 Early Investment Institutions in China” by the Rongzhong Awards and the “Top 50 Best Early Venture Capital Institutions in China” by CVSource.